Thyroid Cancer

Nexavar Approved for Metastatic Differentiated Thyroid Cancer (12-9-2013)

The U.S. Food and Drug Administration (FDA) has approved Nexavar® (sorafenib) for the treatment of metastatic differentiated thyroid cancer. Differentiated thyroid cancer is the most common type of thyroid cancer and can often be cured with surgery and... Continue Reading

Mutations Linked to Drug Response in Medullary Thyroid Cancer (11-15-2013)

Metastatic medullary thyroid cancers with certain genetic mutations respond better to treatment with Cometriq™ (cabozantinib) than tumors without those mutations, according to the results of a study presented at the 83rd Annual Meeting of the American... Continue Reading

TSH Suppression after Thyroidectomy May Not Be Beneficial (11-4-2013)

Suppression of thyroid-stimulating hormone (TSH) after thyroidectomy for low-risk cancer does not appear to reduce the risk of cancer recurrence and may even increase the risk of osteoporosis in women, according to the results of a study presented at... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (09-16-2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Thyroid Ultrasound May Cut Biopsy Rate (09-13-2013)

Thyroid ultrasound may help identify certain characteristics of thyroid nodules that can predict the likelihood of cancer—and subsequently help determine whether biopsy is necessary, according to the results of a study published in the Journal of the... Continue Reading

Nexavar Shows Promise Against Aggressive Thyroid Cancers (06-17-2013)

The targeted drug Nexavar® (sorafenib) delays the growth of treatment-resistant, differentiated thyroid cancers. These results—from a Phase III clinical trial—were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology... Continue Reading

BRAF V600E mutation Increases Death Risk in Papillary Thyroid Cancer (06-5-2013)

The presence of the BRAF V600E mutation is significantly associated with increased cancer-related death among patients with papillary thyroid cancer, according to the results of a study published in the Journal of the American Medical Association. The... Continue Reading

Following Lifestyle Recommendations Reduces Risk of Cancer Death (05-15-2013)

People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading

Selumetinib May Reverse Radioiodine Resistance in Advance Thyroid Cancer (03-28-2013)

The experimental drug selumetinib (AZD6244) may help some patients with advanced thyroid cancer overcome resistance to radioiodine, which is the most effective treatment for the disease, according to the results of a study published in the New England... Continue Reading

Cancer Deaths on the Decline (02-11-2013)

Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading

« Previous PageNext Page »